Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design
Abstract Background The symptom severity of a substantial group of schizophrenia patients (30–40%) does not improve through pharmacotherapy with antipsychotic medication, indicating a clear need for new treatment options to improve schizophrenia outcome. Meta-analyses, genetic studies, randomized co...
Main Authors: | Lyliana G. Nasib, Iris E. Sommer, Inge Winter - van Rossum, Jacqueline de Vries, Shiral S. Gangadin, Priscilla P. Oomen, Gurmeet Judge, Renske E. Blom, Jurjen J. Luykx, Nico J. M. van Beveren, Natalie D. Veen, Rune A. Kroken, Erik L. Johnsen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-04365-4 |
Similar Items
-
Atopy Increases Risk of Psychotic Experiences: A Large Population-Based Study
by: Marieke J.H. Begemann, et al.
Published: (2019-07-01) -
Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration
by: Lieven Van Meulebroek, et al.
Published: (2017-08-01) -
Effects of methyl prednisolone in early ARDS
by: Nasef Abdelsalam Rezk, et al.
Published: (2013-01-01) -
Are saponins and sapogenins precursors of prednisolone? Preliminary results
by: Giuseppe Federico Labella, et al.
Published: (2015-11-01) -
Treatment of ITP, prednisolone versus IVIG: a 12 month study in Children's Medical Center
by: Ramyar A, et al.
Published: (2008-06-01)